358 related articles for article (PubMed ID: 35594163)
1. Cancer Immunoediting in the Era of Immuno-oncology.
Gubin MM; Vesely MD
Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunoediting and resistance to T cell-based immunotherapy.
O'Donnell JS; Teng MWL; Smyth MJ
Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution.
Wu T; Wang G; Wang X; Wang S; Zhao X; Wu C; Ning W; Tao Z; Chen F; Liu XS
Cancer Res; 2022 Jun; 82(12):2226-2238. PubMed ID: 35486454
[TBL] [Abstract][Full Text] [Related]
4. Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
Liu S; Sun Q; Ren X
J Hematol Oncol; 2023 Apr; 16(1):38. PubMed ID: 37055849
[TBL] [Abstract][Full Text] [Related]
5. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research.
Overgaard NH; Fan TM; Schachtschneider KM; Principe DR; Schook LB; Jungersen G
ILAR J; 2018 Dec; 59(3):247-262. PubMed ID: 30476148
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
Vesely MD; Schreiber RD
Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic applications of the cancer immunoediting hypothesis.
Desai R; Coxon AT; Dunn GP
Semin Cancer Biol; 2022 Jan; 78():63-77. PubMed ID: 33711414
[TBL] [Abstract][Full Text] [Related]
8. From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology.
Aragon-Sanabria V; Kim GB; Dong C
Adv Exp Med Biol; 2018; 1092():113-138. PubMed ID: 30368751
[TBL] [Abstract][Full Text] [Related]
9. The immunobiology of cancer immunosurveillance and immunoediting.
Dunn GP; Old LJ; Schreiber RD
Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
[TBL] [Abstract][Full Text] [Related]
10. Computational Quantification of Cancer Immunoediting.
Liu K; He S; Sun S; Zhang X; He Y; Quan F; Pang B; Xiao Y
Cancer Immunol Res; 2023 Sep; 11(9):1159-1167. PubMed ID: 37540180
[TBL] [Abstract][Full Text] [Related]
11. Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming.
Diamond MS; Lin JH; Vonderheide RH
Cancer Immunol Res; 2021 Aug; 9(8):877-890. PubMed ID: 34145076
[TBL] [Abstract][Full Text] [Related]
12. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Mittal D; Gubin MM; Schreiber RD; Smyth MJ
Curr Opin Immunol; 2014 Apr; 27():16-25. PubMed ID: 24531241
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer.
Lee MY; Allen CT
Head Neck; 2020 Sep; 42(9):2722-2733. PubMed ID: 32275098
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances of RNA m
Ma S; Barr T; Yu J
Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
[TBL] [Abstract][Full Text] [Related]
15. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
Matsushita H; Vesely MD; Koboldt DC; Rickert CG; Uppaluri R; Magrini VJ; Arthur CD; White JM; Chen YS; Shea LK; Hundal J; Wendl MC; Demeter R; Wylie T; Allison JP; Smyth MJ; Old LJ; Mardis ER; Schreiber RD
Nature; 2012 Feb; 482(7385):400-4. PubMed ID: 22318521
[TBL] [Abstract][Full Text] [Related]
16. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
[TBL] [Abstract][Full Text] [Related]
17. Immune approaches to the treatment of breast cancer, around the corner?
Criscitiello C; Esposito A; Gelao L; Fumagalli L; Locatelli M; Minchella I; Adamoli L; Goldhirsch A; Curigliano G
Breast Cancer Res; 2014 Feb; 16(1):204. PubMed ID: 25774617
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and Gut Microbiota in Cancer Immunoediting, CD8/Treg Ratios, Immune Cell Homeostasis, and Cancer (Immuno)Therapy: Concise Review.
Kareva I
Stem Cells; 2019 Oct; 37(10):1273-1280. PubMed ID: 31260163
[TBL] [Abstract][Full Text] [Related]
19. [Cancer Immunoediting in the Development of Cancer Immunotherapy].
Ariyasu R; Nishikawa H
Gan To Kagaku Ryoho; 2019 Mar; 46(3):407-411. PubMed ID: 30914573
[TBL] [Abstract][Full Text] [Related]
20. The senescence journey in cancer immunoediting.
Zingoni A; Antonangeli F; Sozzani S; Santoni A; Cippitelli M; Soriani A
Mol Cancer; 2024 Apr; 23(1):68. PubMed ID: 38561826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
